Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Molecular Partners AG Sponsored ADR (MOLN) vs Outlook Therapeutics, Inc. (OTLK)

Molecular Partners AG Sponsored ADR and Outlook Therapeutics, Inc. are both Biotechnology companies. Molecular Partners AG Sponsored ADR and Outlook Therapeutics, Inc. are of similar size ($160.5M and $159.5M). Molecular Partners AG Sponsored ADR grew revenue faster over the last twelve months: −28.0% against −113.6%. Outlook Therapeutics, Inc. has the higher net margin (5,253.4% vs 0.00%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Outlook Therapeutics, Inc. leads on 10 and Molecular Partners AG Sponsored ADR on 5.

Valuation

Metric MOLN OTLK Biotechnology median
P/E n/m n/m 7.88
P/S 28.96 n/m 11.47
P/B 2.21 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 13.74 (90.78) 10.73
Earnings yield (40.52%) (163.17%) (28.84%)
Free cash flow yield (35.09%) (64.67%) (23.03%)

Profitability

Metric MOLN OTLK Biotechnology median
Gross margin 0.00% 195.62% 65.16%
Operating margin 0.00% 4,781.76% 0.00%
Net margin 0.00% 5,253.40% 0.00%
Free cash flow margin 0.00% 4,826.38% 0.00%
Return on equity (63.89%) 256.92% (57.72%)
Return on assets (52.73%) (251.66%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric MOLN OTLK Biotechnology median
Revenue growth (TTM) (27.99%) (113.55%) 5.64%
EPS growth (last fiscal year) (9.94%) 55.81% —
Revenue growth, 5-year CAGR (23.12%) (22.99%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MOLN OTLK Biotechnology median
Debt to equity 0.00 (1.75) 0.00
Current ratio 7.27 0.81 4.73
Net debt to EBITDA 1.66 (0.33) 0.96

Dividend

Metric MOLN OTLK Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric MOLN OTLK Biotechnology median
Market cap 160.52m 159.48m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack